Coherus BioSciences Inc (CHRS)
Coherus BioSciences Inc. is a biotechnology company focused on developing and commercializing cancer immunotherapies in the United States. Its portfolio includes UDENYCA, a biosimilar referencing Neulasta; LOQTORZI, a programmed death receptor-1 inhibitor; and several investigational programs, including Casdozokitug and CHS-114. The company also maintains collaboration, license, and out-licensing agreements with several biopharmaceutical partners, including Junshi Biosciences, Surface, Adimab LLC, Bioeq AG, Genentech, Vaccinex, Novartis Institutes for Biomedical Research, and GlaxoSmithKline Intellectual Property No. 4 Limited. Incorporated in 2010 and based in Redwood City, California, it was formerly known as Coherus BioSciences, Inc. before adopting the Coherus Oncology, Inc. name in May 2025.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CHRS
|
$1.57
|
9.1% Upside
|
Fair
|
$7.80
|
441.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-1.3x
|
2.8x
|
4.7x
|
219 M
|
109.4 M
|
19.9%
|
87.7%
|
-10.2
|
—
|
98.8%
|
